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626Objectives: Alveolar-pleural fistulas causing persistent air leaks are conditions associated with prolonged
hospital courses, high morbidity, and possibly increased mortality. Intrabronchial valves serve as a noninvasive
therapeutic option for the closure of alveolar-pleural fistulas.
Methods: The present review describes a brief history of, and indications for, the placement of intrabronchial
valves in patients with persistent air leaks. The essential steps necessary for placement are air leak isolation,
airway sizing, and valve deployment. Additionally, the indications and methods for intrabronchial valve re-
moval, along with the potential complications from intrabronchial valve placement, are described.
Conclusions: The increased use of intrabronchial valves in the treatment of persistent air leaks requires bron-
choscopists and clinicians to understand the procedural steps and techniques necessary for intrabronchial valve
placement. (J Thorac Cardiovasc Surg 2013;145:626-30)Intrabronchial valves (IBVs) are small umbrella-shaped de-
vices designed to limit airflow to distal portions of the lung.
The IBVs are placed into the desired airways using a flexible
bronchoscope and are removable. Although a number of re-
cent studies have described the utility of IBVs for the treat-
ment of persistent air leaks (PALs) after alveolar-pleural
fistulas (APFs) due to pneumothoraces, a clear explanation
of placement techniques have rarely been reported in detail.
The present report describes the step-by-step process to iso-
late the air leaks and then properly place the IBVs.
Bronchial valves were initially developed as an investiga-
tional approach for the bronchoscopic treatment of emphy-
sema by lung volume reduction. Designed to isolate the
airway segments, the valves induce atelectasis in the
emphysematous lung segments. These studies involved 2
types of airway valves: the IBV system (Spiration,
Redmond, Wash) and the Zephyr (Emphasys, Redwood
City, Calif).1-3 Although study of the Emphasys valves in
the Endobronchial Valve for Emphysema Palliation
Trial (VENT) showed improvements in lung function,
exercise tolerance, and symptoms, an increased incidence
was found in the exacerbation frequency of chronic
obstructive pulmonary disease, an increased incidence of
pneumonia, and an increase incidence of hemoptysis after
implantation.4 Currently, Zephyr valves are not approved
for use in the United States. Spiration IBVs continue to be
studied for use in severe emphysema and are considered in-
vestigational for the management of emphysema.e University of Chicago Medical Center, Chicago, Ill.
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The Journal of Thoracic and Cardiovascular SurgDuring the clinical trials of both the Zephyr and the Spi-
ration valves, several valves were placed in compassionate
use scenarios to control PALs. Clinical series by Gillespie
and colleagues5 and Travaline and colleagues6 have demon-
strated the safe and efficacious use of these technologies to
aid in the management of PALs resulting from APFs. Al-
though they have not been studied in randomized controlled
studies, the IBV system has been approved through the Hu-
manitarian Device Exemption for PALs after segmentec-
tomy, lobectomy, and lung volume reduction surgery.
Additionally, a number of physicians have used IBVs in
the off-label treatment of APFs to correct PALs and even
aid in weaning from significant oxygen support and me-
chanical ventilation in intensive care unit patients.7,8
Bronchopleural fistulas are pathologic communications
between the bronchial tree and the pleural space, and
APFs are pathologic communications between the alveoli
and the pleural space. These communications can arise
from a number of conditions, including, but not limited
to, pneumothoraces, pulmonary infections, trauma, malig-
nancies, and complications after thoracic surgery. Both of
these processes can result in the creation of PALs that
can result in high morbidity, increased mortality, and
prolonged hospitalization.9-11 A number of therapeutic
options, both invasive and noninvasive, are available for
the treatment of PALs secondary to bronchopleural
fistulas. Noninvasive approaches to therapy include
prolonged chest tube drainage with tailored ventilator
strategies aimed at establishing acceptable ventilation and
oxygenation while reducing flow through the fistula.12,13
Invasive therapies include pleural abrasion, application
of fibrin sealant, bronchial stump stapling, muscle
flap construction, omental flap coverage, and surgical
lobectomy. The use of devices previously used in
vascular surgery, such as Amplatzer vascular plugs, are
even being explored in the treatment of PALs.14 A
2001 American College of Chest Physicians consensusery c March 2013
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APF ¼ alveolar-pleural fistula
EBV ¼ endobronchial valve
IBV ¼ intrabronchial valve
PAL ¼ persistent air leak
VENT ¼ Endobronchial Valve for Emphysema
Palliation Trialstatement concluded that bronchoscopy had no role in
controlling PALs, despite numerous series documenting
their effectiveness.
A persistent pulmonary air leak is defined as an air leak
present on postoperative day 7 after lobectomy, segmentec-
tomy, or lung volume reduction surgery, unless present only
during forced exhalation or cough. An air leak present on
day 5 should be considered for treatment if it is continuous,
present during the normal inhalation phase of inspiration, or
is present on normal expiration and is accompanied by sub-
cutaneous emphysema or respiratory compromise. Gilles-
pie and colleagues5 described 7 patients with complex
APFs controlled using IBVs. During the 15-month period,
8 bronchoscopies for valve placement were performed in
7 patients, resulting in a reduction of air leaks in all the pa-
tients. The median duration of air leak was 4 weeks before
treatment. After IBV placement, the median air leak dura-
tion was 1 day (mean, 4.5 days).5 Recently, a number of
IBV studies have described success in treating intensive
care unit patients with various etiologies for APFs, includ-
ing traumatic chest tube placement and spontaneous pneu-
mothoraces.7,8 These case series have demonstrated
that treatment of APFs in the setting of significant
ventilatory support has led to successful weaning from
mechanical ventilation and down titration of high levels
of supplemental oxygen.
The IBV is an umbrella-shaped device of various sizes
(5, 6, and 7 mm diameter). The valves themselves are
made of a Nitinol framewith a polymer membrane, creating
the umbrella appearance (Figure 1). The membrane is held
against the airway mucosa by 6 flexible struts. Distal an-
chors help hold the valve in place by embedding into the air-
way. This construction allows the valve to expand and
contract with airway movement during respiration. The de-
sign permits the valve to limit airflow to distal portions of
the lungs, while still allowing drainage of secretions into
the proximal airways. The IBV can easily be removed
from the airway after resolution of the PAL by pulling on
the rod tip situated in the middle of the umbrella portion
of the structure with bronchoscopy forceps. Only minor air-
way trauma, similar to that seen with cytology brushing,
will occur with removal.The Journal of Thoracic and CaOVERVIEW OF IBV PLACEMENT
The placement process of IBVs is a collection of steps
aimed at identifying and occluding the lung segments con-
tributing to the PALs. These steps include air leak isolation,
airway sizing, and valve deployment.Air Leak Isolation
Identifying the offending segment containing the PAL is
a critical step in the placement of IBVs. Although it might
seem intuitive to the treating physician that one should
‘‘know’’ where an air leak is originating, frequently more
than 1 airway is involved in the PAL. Because the IBV iso-
lates that region of the lung, it is imperative to know which
segments require valve placement to avoid occlusion of
viable lung not involved in the PAL.
Several methods for air leak isolation have been de-
scribed but the most reliable continues to be sequential bal-
loon occlusion of segmental airways, moving proximally to
distally. This is accomplished by using a simple balloon
catheter. We begin by first occluding each mainstem bron-
chus to demonstrate whether we can truly ‘‘stop’’ the air
leak. We then proceed distally and occlude the whole upper
lobe. If no change occurs in the degree of the air leak, we
isolate the lower lobe (and if on the right, the middle lobe
at the same time). Once we have identified the target lobe,
we test each individual segment. This systematic approach
allows the detection of complex air leaks involving more
than 1 segment and/or more than 1 lobe. Various other
methods have been studied in an effort to isolate PALs,
such as the use of nuclear medicine, selective bronchogra-
phy, and exhaled volumes on the ventilator (D. Feller-
Kopman, personal communication, May 2012).15,16
During air leak isolation,we recommend at least an 8.5F or
larger endotracheal tube to prevent ‘‘artificial’’ occlusion of
the air leak by the bronchoscope. The current IBV system
available in the United States requires a 2.8-mm working
channel (the European system requires a 2.0-mm working
channel). Visualization of the pleural drainage device should
be arranged so the interventional team can search for reduc-
tion in the air leak during occlusion of the suspected airways.
During each occlusion, it is recommended to wait several re-
spiratory cycles (roughly 5 breaths) to determine the effect of
airway occlusion on the air leak. After occlusion, residual air
remains in the distal portion of the airway and in the pleural
space. After 4 to 5 breath cycles, the air should be evacuated
from the pleural space, allowing the operator to judgewhether
a reduction of airflow through the defect has truly occurred.
A reduction in the size of the air leak should indicate that
the operator is following the correct path to the involved seg-
ment, and an increase in the air leak should represent redistri-
bution of more air from a normal segment through the defect.
The source of air leaks can be quite variable depending
on the precipitating event that induced the PAL. Therdiovascular Surgery c Volume 145, Number 3 627
FIGURE 1. A, Close-up view of intrabronchial valve. B, Close-up view, labeled. Provided by Spiration Inc (Redmond, Wash).
Expert Review Mahajan et alpresence of numerous defects, especially involvingmultiple
segments or multiple lobes, often involves prolonged proce-
dural times for isolation and might ultimately require de-
ployment of several valves. In our experience, our
patients have required 2 to 9 valves to control PALs.
IBV Sizing
Once the air leak has been isolated, the first step is to size
the airway to determine the correct IBV to be placed. The
IBV system comes with an airway sizing kit that calibrates
a balloon catheter (Olympus B5-2C balloon catheters or
Applied Medical balloon catheters, Python EC 11 mm/5F)
to measure the airway diameter and determine the valve
size for deployment. The deflated balloon should be ad-
vanced to the opening of the airway and slowly inflated until
the balloon has made gentle contact with the airway walls
(Figure 2). Once the balloon has been inflated and made cir-
cumferential contact with all portions of the airway wall, an
attempt should be made to advance and withdraw the bal-
loon gently to ensure no migration occurs distally or prox-
imally of the balloon within the airway. An appropriate
inflation volume should provide the beginning of drag on
the airway with movement of the balloon. The balloon
should not be overinflated causing dilation or distension
of the airway. The degree of balloon inflation should corre-
spond to the valve size. Inaccurate sizing of the airway can
result in a poor seal of the airway and allow the PAL to
continue.FIGURE 2. Diagram showing balloon occlusion.
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Valve deployment is a multistep process using the IBV
catheter. Once the single-use valve is loaded, the catheter
tip should be inspected to guarantee the valve has been ap-
propriately loaded and no valve anchors are protruding from
the catheter. With the bronchoscope resting in a more prox-
imal, larger airway, the catheter is advanced out of the bron-
choscope so the compressed valve can been visualized. The
stabilization rod is separated from the stabilization wire by
roughly 1 mm, requiring the operator to ‘‘close the gap’’ to
improve the deployment accuracy and prevent kinking of
the catheter (Figure 3).With the bronchoscope in the neutral
position, the safety clip should be removed from the most
proximal portion of the catheter, and the catheter handle
should be gently pressed to eliminate the space between
the removal rod and stabilization wire. The catheter and
valve should then be retracted into the bronchoscope. At
this point, the bronchoscope can be directed to the target air-
way. Once the target airway has been visualized, the cathe-
ter should be advanced distally to the target location, with
constant attention paid to the black valve line signifying
the deployment site. The catheter is then pulled proximally
to align the valve line with the desired valve placement lo-
cation. At the end of maximum inhalation, the retractor han-
dle should be squeezed gently with persistent pressure to
deploy the IBV into place. Valve deployment should be per-
formed in 1 continuous motion within 1 to 2 seconds. The
deployed valve should be observed after placement intoProvided by Spiration Inc (Redmond, Wash).
ery c March 2013
FIGURE 3. Diagram showing closing the gap. Provided by Spiration Inc
(Redmond, Wash).
Mahajan et al Expert Reviewthe airway for 25 to 30 seconds to ensure proper positioning
(Figure 4). After valve placement, the air leak chamber of
the chest tube collecting system should be observed for 4
to 5 ventilatory cycles to assess any changes in the degree
of the air leak. During this period, occlusion of the culprit
airway might divert airflow to other areas of the lung, un-
masking additional air leaks that might not have been appre-
ciated during the air leak identification process. These steps
should be repeated as necessary for each segment needing
valve placement.
IBV Removal
The criteria for IBV removal vary and depend on clinical
judgment. Resolution of air leaks with adequate time for tis-
sue healing is a well-accepted indication for IBV removal.
Physicians should re-evaluate patients approximately 6
weeks after valve placement to determine whether IBV re-
moval is a feasible option. Additionally, if surgical interven-
tion is planned because of an inability to correct the PAL
using IBVs, all valves should be removed bronchoscopi-
cally before surgery. Removal of the IBVs should be per-
formed using either cupped or rat-toothed forceps. The
use of an endotracheal tube is recommended to facilitate
ventilation and anesthesia and, most importantly, to protect
the vocal cords and other upper airway structures from dam-
age as the IBVs are withdrawn from the patient. IBVFIGURE 4. A and B, Endoscopic v
The Journal of Thoracic and Caremoval does not require a 2.8-mm working channel, be-
cause the valves are not drawn into the bronchoscope chan-
nel. The removal of the IBVs requires the bronchoscopist to
grasp the removal rod shaft and gently pull proximally until
the IBV has been dislodged from the airway wall (Figure 5).
Before removal of the IBV into the endotracheal tube, the
IBV should be pulled as close as possible to the end of
the bronchoscope. The bronchoscope and forceps should
be pulled out simultaneously through the endotracheal
tube. In the setting of a normal coagulation panel, only min-
imal bleeding should occur during the removal process.Complications of IBV Placement
The list of complications from IBV placement is a com-
posite of the complications observed during clinical trials
focusing on lung volume reduction for emphysema, because
no specific trials have been conducted to observe placement
of IBVs for PALs. The possible complications are listed in
the ‘‘Instruction for Use’’ packet included with the IBV sys-
tem (Table 1). The VENT trial succeeded in confirming a fa-
vorable safety profile for the use of endobronchial valves,
showing that by 6 months, the rate of the composite of 6 ma-
jor complications was 6.1% in the endobronchial valve
(EBV) group and 1.2% in the control group (P¼ .08), a level
that met the prespecified safety criteria.4 Additionally,
follow-up through 12months continued to show a complica-
tion profile that was not significant between the EBV and
control groups. The most common adverse event observed
in the VENT trial were pneumonia in the segment distal to
valve placement. All cases of pneumonia resolved with the
use of antibiotics, with 6 patients requiring hospitalization,
none of whom required mechanical ventilation. Addition-
ally, the presence of hemoptysis (defined as bleeding requir-
ing bronchoscopic inspection) during both early (within 90
days of the procedure) and late (3-12months after the proce-
dure) follow-up was significantly increased in the EBViews showing valve in airway.
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FIGURE 5. Diagram showing intrabronchial valve removal. Provided by
Spiration Inc (Redmond, Wash).
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exacerbations of chronic obstructive pulmonary disease re-
quiring hospitalization occurred more often in the EBV
group (7.9%) than in the control group (1.1%, P ¼ .03)
but at a similar rate during late follow-up (P ¼ .84).
Our institutional experience involved approximately 25
patients with placement of IBVs for PALs. The etiologies
for our cohort ranged from spontaneous pneumothoraces
to inadvertent placement of chest tubes into the lung paren-
chyma. In most cases, because the IBVs were ultimately re-
moved once the air leak had resolved (typically 6 weeks
after placement), many of the complications described in
the VENT trial were infrequently seen in our experience us-
ing IBVs for PALs. No deaths, cardiovascular complica-
tions, pulmonary complications, or implant-related events
have been related to the placement of IBVs. Although
rare, the most common unexpected event after valve place-
ment was failure to completely resolve the PAL. In the few
cases without complete resolution, the degree of the air leak
was significantly reduced. The postulated explanation for
the inability to completely resolve the identified leaks was
the presence of collateral ventilation. In such instances,
the patients should undergo placement of a pigtail catheter
into the pleural space, with attachment to a dry seal chest
drain and discharge home with appropriate follow-up.CONCLUSIONS
The off-label use of airway valves for the treatment of
PALs has emerged as an increasingly popular therapeuticTABLE 1. Possible complications of IBV placement
Atelectasis
Bleeding observed from an airway treated with an IBV
Bronchitis
Damage in the airway and/or tissue near an IBV
Infection distal to IBV
Local airway swelling or edema at site of IBV implantation
Migration of IBVout of airway or lung
Persistent cough
Pneumothorax
Shortness of breath
Tissue hyperplasia or granulation at site of IBV implantation
Death
IBV, Intrabronchial valve.
630 The Journal of Thoracic and Cardiovascular Surgoption.5,7,8,17,18 The use of IBVs continues to be a safe
and effective option in the hands of experienced
operators. The placement of IBVs is a multistep process
requiring a detailed understanding of the airway anatomy
and a systematic approach to air leak isolation. Although
no formal data have been published regarding the cost/
benefit analysis of IBV use in patients with PALs
secondary to APFs, the reduction of hospital days
observed in patients who have received IBVs compared
with those receiving conventional therapy is likely to
demonstrate the cost effectiveness. The use of IBVs in the
treatment of PALs by interventional pulmonologists
allows for increased awareness of the devices’ capabilities
in other specialties, such as thoracic surgery. IBVs
represent minimally invasive technology capable of
providing thoracic surgeons with an effective therapeutic
option for the treatment of PALs.References
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